Banque Transatlantique SA Buys Shares of 651,859 Boston Scientific Co. (NYSE:BSX)

Banque Transatlantique SA bought a new stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 651,859 shares of the medical equipment provider's stock, valued at approximately $57,272,000. Boston Scientific makes up approximately 1.4% of Banque Transatlantique SA's investment portfolio, making the stock its 20th largest holding.

Several other large investors have also added to or reduced their stakes in the business. World Investment Advisors LLC boosted its holdings in shares of Boston Scientific by 50.9% during the 3rd quarter. World Investment Advisors LLC now owns 11,684 shares of the medical equipment provider's stock worth $979,000 after buying an additional 3,939 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of Boston Scientific in the 3rd quarter valued at $1,175,000. Synovus Financial Corp lifted its position in shares of Boston Scientific by 7.1% during the 3rd quarter. Synovus Financial Corp now owns 17,518 shares of the medical equipment provider's stock valued at $1,468,000 after acquiring an additional 1,167 shares during the period. B. Riley Wealth Advisors Inc. boosted its stake in Boston Scientific by 36.2% during the third quarter. B. Riley Wealth Advisors Inc. now owns 15,553 shares of the medical equipment provider's stock worth $1,303,000 after acquiring an additional 4,136 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in Boston Scientific by 5.9% in the third quarter. Principal Financial Group Inc. now owns 2,010,441 shares of the medical equipment provider's stock worth $168,475,000 after purchasing an additional 111,724 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BSX. Needham & Company LLC increased their price objective on shares of Boston Scientific from $113.00 to $115.00 and gave the stock a "buy" rating in a research report on Thursday, April 24th. Robert W. Baird increased their price target on Boston Scientific from $115.00 to $120.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Barclays boosted their price objective on Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, April 25th. Stifel Nicolaus increased their target price on Boston Scientific from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Thursday, February 6th. Finally, UBS Group lifted their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research report on Friday, February 7th. Twenty-three equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and an average target price of $114.52.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,314 shares of the company's stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $102.06, for a total transaction of $1,767,066.84. Following the sale, the executive vice president now directly owns 22,235 shares of the company's stock, valued at $2,269,304.10. This represents a 43.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the completion of the transaction, the senior vice president now owns 36,193 shares of the company's stock, valued at $3,441,592.37. The trade was a 11.77 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 307,025 shares of company stock worth $31,742,060. Insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

NYSE:BSX traded down $0.02 during trading on Tuesday, reaching $104.22. The company's stock had a trading volume of 5,174,388 shares, compared to its average volume of 6,341,116. The firm has a market cap of $154.15 billion, a price-to-earnings ratio of 83.38, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 12 month low of $71.88 and a 12 month high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a 50 day moving average of $98.71 and a 200-day moving average of $95.66.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The business had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The firm's quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter last year, the company posted $0.56 earnings per share. Research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.